{"id":"W4405050504","doi":"10.1016/j.esmoop.2024.103972","title":"Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; Foundation Medicine; XBiotech; EMD Serono; Genentech; National Institutes of Health; HCA Healthcare; Pfizer; Incyte; Moderna; Revolution Medicines; Gilead Sciences; National Cancer Institute; Vertex Pharmaceuticals; F. Hoffmann-La Roche; Eli Lilly and Company; AstraZeneca; Jounce Therapeutics; Celgene; Array BioPharma; Astellas Pharma; TG Therapeutics; Seagen; Agios Pharmaceuticals","keywords":"Atezolizumab; Metastatic Urothelial Carcinoma; Urothelial carcinoma; Oncology; Medicine; Urothelial cancer; Internal medicine; Urology; Phase (matter); Bladder cancer; Cancer; Chemistry; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002721769,0.0002422753,0.0005815718,0.0001028843,0.0002640481,0.0002308193,0.0003835799,0.00005709979,0.00229382],"category_scores_gemma":[0.0000349171,0.0001458846,0.000483405,0.0004699389,0.00005916221,0.0001504156,0.00009200665,0.0001570172,0.00006660426],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001043991,"about_ca_system_score_gemma":0.0004876858,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01006331,"about_ca_topic_score_gemma":0.0006587002,"domain_scores_codex":[0.9985353,0.00008751323,0.0003434516,0.0004942166,0.0002565069,0.0002830182],"domain_scores_gemma":[0.9990082,0.0002537075,0.00005875839,0.0005140607,0.00005153182,0.0001137527],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4856434,0.006405748,0.003031535,0.000154796,0.04887893,0.0008303361,0.01384655,0.00005554042,0.001162546,0.003319768,0.106512,0.3301588],"study_design_scores_gemma":[0.4822514,0.01509852,0.005552967,0.0001334939,0.02875086,0.00003299289,0.0004591062,0.007427298,0.006565718,0.005602032,0.4474281,0.0006974765],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9701455,0.002431052,0.004754378,0.008820093,0.001221055,0.007027092,0.002310345,0.0001146011,0.003175836],"genre_scores_gemma":[0.9887794,0.00005943868,0.001264061,0.001260504,0.0009768591,0.001041495,0.0004918468,0.00005495344,0.006071493],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3409161,"threshold_uncertainty_score":0.9986182,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0958352596985449,"score_gpt":0.4042303405836028,"score_spread":0.3083950808850579,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}